Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells

doi:10.1038/s41375-020-0719-y

Case Reports

. 2020 Jul;34(7):1939-1942.

doi: 10.1038/s41375-020-0719-y. Epub 2020 Jan 24.

Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells

Ivetta Danylesko^{1

2}, Elad Jacoby^{2

3}, Ronit Yerushalmi^{1

2}, Noga Shem-Tov^{1

2}, Michal J Besser^{2

4}, Helly Vernitsky⁵, Victoria Marcu-Malina⁵, Avichai Shimoni^{1

2}, Abraham Avigdor^{1

2}, Arnon Nagler^{6

7}

Affiliations

¹ Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
² Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
⁴ Ella Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel.
⁵ Institute of Hematology, Sheba Medical Center, Ramat Gan, Israel.
⁶ Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel. a.nagler@sheba.health.gov.il.
⁷ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. a.nagler@sheba.health.gov.il.

PMID: 31980731
DOI: 10.1038/s41375-020-0719-y

Case Reports

Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells

Ivetta Danylesko et al. Leukemia. 2020 Jul.

. 2020 Jul;34(7):1939-1942.

doi: 10.1038/s41375-020-0719-y. Epub 2020 Jan 24.

Authors

Affiliations

¹ Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel.
² Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.
⁴ Ella Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel.
⁵ Institute of Hematology, Sheba Medical Center, Ramat Gan, Israel.
⁶ Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel. a.nagler@sheba.health.gov.il.
⁷ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. a.nagler@sheba.health.gov.il.

PMID: 31980731
DOI: 10.1038/s41375-020-0719-y

No abstract available

PubMed Disclaimer

Cited by

Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation.
Liberatore C, Di Ianni M. Liberatore C, et al. Int J Mol Sci. 2023 Oct 9;24(19):15019. doi: 10.3390/ijms241915019. Int J Mol Sci. 2023. PMID: 37834466 Free PMC article. Review.
CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia-Recent Advances.
Zarychta J, Kowalczyk A, Krawczyk M, Lejman M, Zawitkowska J. Zarychta J, et al. Cancers (Basel). 2023 May 27;15(11):2944. doi: 10.3390/cancers15112944. Cancers (Basel). 2023. PMID: 37296906 Free PMC article. Review.
Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives.
Leotta S, Condorelli A, Sciortino R, Milone GA, Bellofiore C, Garibaldi B, Schininà G, Spadaro A, Cupri A, Milone G. Leotta S, et al. J Clin Med. 2022 Jan 4;11(1):253. doi: 10.3390/jcm11010253. J Clin Med. 2022. PMID: 35011994 Free PMC article. Review.
Treatment of AML Relapse After Allo-HCT.
Webster JA, Luznik L, Gojo I. Webster JA, et al. Front Oncol. 2021 Dec 16;11:812207. doi: 10.3389/fonc.2021.812207. eCollection 2021. Front Oncol. 2021. PMID: 34976845 Free PMC article. Review.
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia.
Maucher M, Srour M, Danhof S, Einsele H, Hudecek M, Yakoub-Agha I. Maucher M, et al. Cancers (Basel). 2021 Dec 7;13(24):6157. doi: 10.3390/cancers13246157. Cancers (Basel). 2021. PMID: 34944782 Free PMC article. Review.

See all "Cited by" articles

References

1. Dombret Hervé, Claude Gardin. An update of current treatments for adult acute myeloid leukemia. Blood 2016;127:53–62. - DOI
1. Jacoby E, Shahani SA, Shah NN. Updates on CAR T-cell therapy in B-cell malignancies. Immunol Rev 2019;290:39–59. - DOI
1. Tasian SK. Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? Ther Adv Hematol. 2018;9:135–48. https://doi.org/10.1177/2040620718774268 .
1. Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992;80:470–7
1. Ma G, Wang Y, Ahmed T, Zaslav AL, Hogan L, Avila C, et al. Anti-CD19 chimeric antigen receptor targeting of CD19+ acute myeloid leukemia. Leuk Res Rep 2018;9:42–4. - PubMed - PMC

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- Genetic Alliance
- MedlinePlus Health Information

[1] Dombret Hervé, Claude Gardin. An update of current treatments for adult acute myeloid leukemia. Blood 2016;127:53–62. - DOI

[2] Dombret Hervé, Claude Gardin. An update of current treatments for adult acute myeloid leukemia. Blood 2016;127:53–62. - DOI

[3] Jacoby E, Shahani SA, Shah NN. Updates on CAR T-cell therapy in B-cell malignancies. Immunol Rev 2019;290:39–59. - DOI

[4] Jacoby E, Shahani SA, Shah NN. Updates on CAR T-cell therapy in B-cell malignancies. Immunol Rev 2019;290:39–59. - DOI

[5] Tasian SK. Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? Ther Adv Hematol. 2018;9:135–48. https://doi.org/10.1177/2040620718774268 .

[6] Tasian SK. Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? Ther Adv Hematol. 2018;9:135–48. https://doi.org/10.1177/2040620718774268 .

[7] Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992;80:470–7

[8] Kita K, Nakase K, Miwa H, Masuya M, Nishii K, Morita N, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992;80:470–7

[9] Ma G, Wang Y, Ahmed T, Zaslav AL, Hogan L, Avila C, et al. Anti-CD19 chimeric antigen receptor targeting of CD19+ acute myeloid leukemia. Leuk Res Rep 2018;9:42–4. - PubMed - PMC

[10] Ma G, Wang Y, Ahmed T, Zaslav AL, Hogan L, Avila C, et al. Anti-CD19 chimeric antigen receptor targeting of CD19+ acute myeloid leukemia. Leuk Res Rep 2018;9:42–4. - PubMed - PMC

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells

Affiliations

Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical